Biomaterial Database

Nasal decongestants in the treatment of acute otitis media. 1991

C Dietman

UI	MeSH Term	Description	Entries
D010033	Otitis Media	Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.	Middle Ear Inflammation,Inflammation, Middle Ear
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014663	Nasal Decongestants	Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993)	Decongestant,Decongestants,Nasal Decongestant,Vasoconstrictor Agents, Nasal,Vasoconstrictors, Nasal,Agents, Nasal Vasoconstrictor,Decongestant, Nasal,Decongestants, Nasal,Nasal Vasoconstrictor Agents,Nasal Vasoconstrictors
D016032	Randomized Controlled Trials as Topic	Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.	Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical